ArticlePediatric investigation2025
Global, regional, and national burden of brain and central nervous system cancer in children and adolescents, 1990-2021: A systematic analysis of the Global Burden of Disease study 2021.
Article in Pediatric investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Brain and central nervous system (CNS) cancers are the most common pediatric solid tumors, significantly affecting the patients' life expectancy and quality. Objective: To examine the disease burden of brain and CNS cancer in children and adolescents from 1990 to 2021 across various age groups, sexes, and socio-demographic index levels, at the global, regional, and national levels. Methods: Data, including the incidence, mortality, and disability-adjusted life years (DALYs) of brain and CNS cancer in children and adolescents, were obtained from the 2021 Global Burden of Diseases, Injuries, and Risk Factors Study. Temporal trends were evaluated using the Joinpoint regression model. The relationship between disease burden and socioeconomic development, as well as health inequality, was examined. Results: In 2021, the global age-standardized incidence rate of brain and CNS cancers among patients aged 0-20 years was 1.55 per 100 000 population. From 1990 to 2021, the global age-standardized mortality rate (ASMR) declined from 1.14 to 0.76 per 100 000, and the age-standardized DALY rate (ASDR) decreased from 94.29 to 62.79 per 100 000. Over the past three decades, most regions and countries and territories have shown declining trends in ASMR and ASDR. Global inequality of disease burden persists, with regions possessing higher socioeconomic statuses exhibiting lower ASMR, ASDR, and mortality-to-incidence ratio. Interpretation: The decline in ASMR and ASDR of pediatric brain and CNS cancer indicates improvements in disease management and patient outcomes. Enhancing diagnostic and therapeutic strategies, improving life quality, and promoting health equity are crucial directions for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.